U.S. Federal Court Bans 19 Sellers of Nutritional Supplements Falsely Claiming to Contain Urolithin A

In a lawsuit filed by Timeline, a Swiss manufacturer of a postbiotic Urolithin A ingredient marketed as Mitopure, the U.S. District Court for the District of Massachusetts has issued permanent injunctions against 19 companies that were found to have marketed and sold supplements falsely advertised as containing Urolithin A.

The order, entered July 15 by Judge Myong J. Joun, permanently barred 19 defaulting defendants from manufacturing, marketing, distributing, or selling urolithin A products.

The lawsuit was filed in October 2025, alleging that 30 defendants sold products via online retail platforms and through private drop-ship stores that either contained no detectable urolithin A, or urolithin A at levels materially below what was claimed on labels. In certain cases, defendants were found to have used Timeline’s Mitopure trademark without authorization.

Timeline commissioned independent lab testing on the defendants’ products, demonstrating that they contained either no detectable urolithin A or only a fraction of what was claimed. Defendants were also found to have made false claims about products being made in the U.S., products being vegan, or that products were third-party tested and certified. Defendants were found to have provided false address information on product packaging and listings and included undisclosed filler ingredients.

For defendants that appeared in court, Timeline entered stipulated judgments. For the remaining 19 defendants that failed to appear or otherwise respond to the complaint, the court entered default judgment in Timeline’s favor.

The permanent injunction bars the 19 defendants and those acting in concert with them from importing, marketing, advertising, distributing, offering for sale, or selling any product represented as containing urolithin A. These 19 defendants were ordered to pay damages to Timeline ranging from $500 to more than $2.7 million per defendant, depending on how many fraudulent products were sold. The court tripled damages for certain defendants as “enhanced damages.” In sum, the 19 defendants were ordered to pay Timeline $5.3 million.

The 19 defaulting, permanently enjoined defendants in the case were Kroppsund, Saglikli, Pepeior, Sveikata, Gesundgeist, Vivacityx, Boa Saude, Sundhedsliv, Vivesano, Marafiki, EMAW, DUCRKACS, Glyxcodian, VNNIQ, Hipamus, RGD, Vivalifer, Fitura, and CystoRebalance.